If your cardiologist has mentioned a leaking mitral valve, you have likely heard two very different sounding options: TEER (transcatheter edge to edge repair, often done with a device called MitraClip) and mitral valve replacement. In short, TEER is a catheter based clip that repairs your existing valve without open heart surgery, while replacement removes the damaged valve and substitutes a new one, usually through open heart surgery, though catheter based replacement options are emerging too. The right choice depends on your surgical risk, your valve's anatomy, and how the two options compare on recovery time and long term durability, which is exactly what this guide breaks down.
What Is TEER? How the Procedure Actually Works
TEER treats a leaking mitral (or tricuspid) valve without removing it. Your heart team threads a catheter through a vein in your groin, guides it into your heart using live imaging (transesophageal echocardiography, or TEE, alongside X-ray), and attaches one or more small clips to the leaky edges of your valve leaflets. The clips pull the leaflets closer together so the valve closes more completely, cutting down on the backward leak of blood.
The procedure typically takes two to four hours and is done under general anesthesia, even though there is no chest incision and the heart keeps beating throughout. Most people spend one to three nights in the hospital afterward, compared to five to ten days for open heart valve surgery. MitraClip is the most established device for mitral TEER, with a large and growing real-world track record worldwide; TriClip is the equivalent device used for tricuspid valve TEER.
TEER does not replace anything. Your native valve stays in place, which is why doctors sometimes describe it as a repair rather than a fix.
If breathlessness, swelling, or fatigue have been getting worse over the past few weeks, that trajectory matters more than how you feel today. Ask for a cardiology evaluation now, not at your next routine visit.
Qu’est-ce que le remplacement de la valvule mitrale ?
Valve replacement removes the damaged native valve entirely and substitutes a mechanical or biological (tissue) prosthetic valve in its place. Surgical replacement is traditionally done through open heart surgery with the heart temporarily stopped and blood flow rerouted through a heart lung bypass machine. Newer transcatheter replacement options, such as TMVR (transcatheter mitral valve replacement) and TAVR (transcatheter aortic valve replacement, for the aortic valve specifically), deliver a replacement valve through a catheter instead of open surgery, though these newer routes are not yet an option for every patient or every valve.
Récupération de remplacement chirurgical generally means five to ten days in the hospital and several weeks to a few months before returning to normal activity, often supported by a period of structured cardiac rehabilitation. In exchange, replacement tends to produce a more complete, more durable correction of the leak, particularly in patients whose valve anatomy is too damaged or calcified for a clip to work well.
Where Does Surgical Repair Fit In?
TEER and replacement are not the only two paths. Surgical mitral valve repair, done through open heart surgery, resects damaged leaflet tissue or reinforces the valve with a support ring, but keeps your native valve in place rather than removing it. When a valve is repairable, guidelines generally favor repair over replacement, since a well repaired valve tends to outlast a prosthetic one. TEER is often better understood as the catheter based alternative to surgical repair specifically, because both approaches aim to preserve your native valve; replacement becomes the fallback when the valve is too damaged, calcified, or distorted for either a clip or a surgical repair to work. This article focuses on TEER against replacement because that comparison covers the highest stakes decision, whether to keep your native valve at all. If surgical repair is on the table for you, that is a closer comparison worth its own dedicated read.
TEER vs Valve Replacement: Quick Comparison
| Facteur | TEER (Clip Repair) | Remplacement de la vanne |
| What happens to your valve | Stays in place, leaflets clipped together | Removed and replaced with a prosthetic |
| L’accès | Catheter through a vein in the groin | Open heart surgery (or catheter, for TMVR/TAVR) |
| Anesthésie | General, no chest incision | General, with chest incision for surgical routes |
| séjour hospitalier typique | Entre 1 et 3 jours | Entre 5 et 10 jours |
| Retour à une activité normale | About 1 week for light activity | Plusieurs semaines à quelques mois |
| Residual leak risk | Higher; moderate to severe MR recurs more often | Lower; more complete correction |
| taux de réopération | Somewhat higher over time | Coût en adjuvantation plus élevé. |
| Idéal pour | High surgical risk, elderly, or frail patients with favorable valve anatomy | Younger, lower risk patients, or anatomy too damaged for a clip |
Durability: The Tradeoff Nobody Skips
This is the part patients researching TEER most need to understand clearly. Clinical data comparing MitraClip to surgical repair or replacement consistently shows the same pattern: TEER offers a gentler procedure and a much faster recovery, but replacement (and surgical repair) tends to hold up better over time.
In direct comparisons, patients treated with MitraClip have had residual moderate to severe mitral regurgitation more often at hospital discharge than patients treated surgically, and that gap persists at five years of follow up. Surgical approaches generally show lower rates of needing a second procedure down the line. None of this means TEER is a worse choice; it means TEER trades some long term durability for a dramatically lower procedural burden, which is exactly the right trade for a patient who could not safely tolerate open heart surgery in the first place.
Who Is a Good Candidate for TEER?
TEER is generally offered to patients who meet several criteria together, not just one: Surgical risk is elevated, based on a formal risk score (an STS score of 8 percent or higher for replacement risk, or 6 percent or higher for repair risk), significant frailty, or major organ dysfunction that makes open heart surgery riskier than usual.
Symptoms and severity fit the profile: moderate to severe or severe mitral regurgitation (grade 3 or higher), with heart failure symptoms in NYHA class II, III, or ambulatory class IV, and a left ventricular ejection fraction of at least 20 percent.
Valve anatomy is favorable. The most reliable results come from leaflet anatomy that allows the clip to grip and coapt properly, classically an isolated middle scallop (P2) prolapse of the posterior leaflet. Leaflets that are too calcified, too restricted, or have too wide a gap between them are often better suited to replacement instead.
Because these factors interact, the decision is made by a multidisciplinary heart team, not by a single number or scan. Candidacy also looks different depending on whether your regurgitation is primary (a structural problem within the valve itself, such as leaflet prolapse) or secondary (caused by a weakened or enlarged heart pulling the valve out of shape); the clinical evidence behind TEER differs between the two, so this distinction should be discussed with your heart team rather than assumed from general criteria alone.
Risks and Complications of TEER
TEER is less invasive than surgery, but it is not risk free. The most common issues are related to the catheter access site in the groin, including bruising, bleeding, or vascular injury, with major vascular complications occurring in roughly 1 to 4 percent of cases. Less commonly, patients can experience clip detachment or partial detachment, damage to the valve leaflets, stroke or other ischemic events, kidney strain from imaging dye, or, rarely, the need for emergency surgery if the clip cannot adequately reduce the leak. Complication rates are generally lower than for open heart surgery, which is precisely why TEER is favored for higher risk patients, but "less risky than surgery" is not the same as "no risk."
Chest tightness, fainting, or a sudden worsening of breathlessness are not symptoms to monitor at home. These warrant same-day medical attention, regardless of which treatment path you eventually choose.
Mitral TEER vs Tricuspid TEER: A Quick Note
Everything above focuses on the mitral valve, but the same clip based approach is used on the tricuspid valve, using a device called TriClip. Tricuspid TEER has its own candidacy rules (patients with a large gap between leaflets, a very dilated valve opening, or pacemaker leads running through the valve tend to do poorly with a clip and may need transcatheter tricuspid valve replacement instead), and there is not yet strong evidence that repair or replacement is clearly better for the tricuspid valve. If tricuspid regurgitation is your specific diagnosis, treat this article as background and ask your heart team which device fits your anatomy.
Making the Choice: What Actually Decides It
There is no single "better" option between TEER and valve replacement; there is only the option that fits your surgical risk, your valve anatomy, and your priorities around recovery time versus long term durability. A heart team, typically including an interventional cardiologist and a cardiac surgeon, reviews your echocardiogram, your overall health, and your personal goals before recommending a path. If you are being evaluated for either option, the most useful question to bring to that appointment is not "which is better" but "which one fits my valve and my risk profile."
The options on this page depend on how much of your heart function is still recoverable. Waiting on a diagnosis you already have does not preserve those options, it narrows them.
If you or a family member has just received a mitral or tricuspid regurgitation diagnosis, the next right step is a conversation with a structural heart specialist who can walk through your imaging and your options in detail. Related reading: one patient's minimally invasive aortic valve journey.
Blogs récents
FAQ
Not exactly interchangeable: MitraClip typically leaves a small amount of residual leak more often than surgery does, and that gap persists over years of follow up. MitraClip is not meant to outperform surgery; it is meant to offer a much safer path for patients who cannot tolerate an open heart operation in the first place, trading some long term durability for a dramatically lower procedural risk.
There is no fixed expiration date on the clip itself, but "lasting" really means how well it keeps controlling the leak over time. Some patients develop recurrent moderate or severe regurgitation years after the procedure and may need a repeat TEER or a later valve replacement. Regular follow up echocardiograms are how your cardiologist tracks this.
Most patients go on a short course of antiplatelet medication after mitral TEER, not lifelong full anticoagulation, though this varies by device, valve, and individual risk factors like atrial fibrillation. Tricuspid valve replacement devices tend to carry a higher likelihood of needing ongoing anticoagulation than a mitral clip. Your cardiologist will set the specific plan based on your case.
Yes, a clip can partially detach or the leak can recur despite the clip. If that happens, options usually include a repeat TEER procedure, or moving on to surgical or transcatheter valve replacement, depending on your anatomy and how much your risk profile has changed since the first procedure. Failure does not mean you are out of options.
TEER is most often used in older or higher risk patients because that is the population where its lower procedural burden matters most, but age alone is not the deciding factor. A younger patient with prohibitive surgical risk from other conditions can still be a TEER candidate, and an older patient with favorable anatomy and low surgical risk may still be steered toward surgical repair. The heart team looks at risk scores and anatomy together, not age by itself.
Most TEER patients spend one to three days in the hospital and are back to light daily activity within about a week, since there is no chest incision or bypass machine involved. Surgical valve replacement generally means five to ten days in the hospital and several weeks to a few months of recovery, including restrictions on lifting and driving while the breastbone heals. Some post-TEER patients complete a short cardiac rehabilitation program to rebuild stamina, even though the procedure itself is far less invasive.
Medication (typically diuretics and heart failure therapies) can manage symptoms and is often tried first, but it does not fix a structurally leaking valve. TEER or replacement is generally considered once regurgitation is moderate to severe or severe, symptoms are significant, and medication alone is no longer controlling them well. Your cardiologist tracks valve severity and heart function over time to decide when it is time to move beyond medication.
No, and this is a common mix-up. TAVR (transcatheter aortic valve replacement) replaces the aortic valve with a new prosthetic valve delivered by catheter; TEER repairs the mitral or tricuspid valve by clipping the existing leaflets together without removing anything. They treat different valves using fundamentally different approaches, though both are catheter based and avoid open heart surgery.
Dr. Basim Parvez est physiothérapeute agréé et consultant principal auprès des patients chez HOSPIDIO. Titulaire d'un MBA en gestion de la santé, il possède une vaste expérience clinique et une approche empreinte de compassion, et accompagne les patients tout au long de leurs traitements médicaux. Dr. Basim met également à profit son talent d'écriture pour simplifier des informations complexes en matière de santé, permettant ainsi aux patients de prendre des décisions éclairées et favorisant la clarté et la confiance dans leur parcours médical.
Sasmita Bal est spécialiste du marketing digital et du contenu chez HOSPIDIO, experte en SEO et en contenu relatif à la santé internationale. Elle vérifie les contenus publiés afin d'optimiser leur visibilité dans les moteurs de recherche et de garantir leur pertinence par rapport aux besoins des patients internationaux souhaitant se faire soigner en Inde. Tous les contenus qu'elle examine sont rédigés et validés cliniquement par le fondateur de HOSPIDIO et les spécialistes médicaux concernés avant leur publication.